Vaxart's Dynavax Deal Fuels Oral Vaccine Push Beyond COVID-19

NEW YORK, NY – November 13, 2025

Vaxart, Inc. is gaining momentum in the race to revolutionize vaccine delivery, bolstered by a recently announced licensing agreement with Dynavax Technologies and promising data from its clinical programs. The partnership and encouraging results are shifting the company’s focus beyond COVID-19, potentially opening doors to a broader range of infectious disease applications and a new era of convenient immunization.

A Strategic Alliance to Advance Oral Vaccine Technology

The core of Vaxart’s recent progress is the exclusive license agreement with Dynavax, valued at up to $700 million in potential milestone payments and royalties. This deal provides Vaxart with immediate financial relief and, critically, hands off the potentially expensive late-stage development and commercialization of its oral COVID-19 vaccine candidate to a partner with established expertise. “This collaboration is a validation of our oral vaccine platform and its potential to address a significant unmet need,” noted an industry analyst. “The financial terms demonstrate a strong belief in the technology.”

The agreement allows Vaxart to focus on its broader pipeline, including its advanced norovirus vaccine program, while Dynavax shoulders the risk associated with navigating the complex regulatory landscape and scaling up production. Dynavax's involvement underscores the growing interest in oral vaccine delivery, offering advantages such as ease of administration, reduced costs, and potentially improved accessibility, particularly in resource-limited settings. This could overcome traditional cold-chain storage requirements, enabling broader distribution.

Beyond COVID-19: Norovirus Data Signals Platform Potential

While the Dynavax deal centers around COVID-19, the real long-term promise of Vaxart lies in its norovirus vaccine candidate. Recent Phase 1 data revealed significantly enhanced immune responses with its second-generation constructs, inducing a substantial increase in norovirus-blocking antibodies and fecal IgA.